Focus shifts to SID meeting on May 14 for biomarker data that could support soquelitinib's differentiated profile. No near-term revenue catalysts. Monitor Phase 2 AD enrollment updates.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $15.55entry
- T+1 · 6mo ago +1.67%α +1.44% · $15.81
- T+5 · 6mo ago −12.19%α −13.65% · $13.66
- T+20 · 5mo ago −28.49%α −28.51% · $11.12
- T+60 · 3mo ago −10.48%α −15.32% · $13.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.
Key Financial Metrics
Key Facts
- Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
- Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
- Phase 2 atopic dermatitis trial initiated in Q1 2026
- Registrational Phase 3 PTCL trial enrollment continues
- New soquelitinib data to be presented at SID Annual Meeting May 13-16, 2026
Financial Impact
EPS $0.01 miss on $0.14 consensus is marginal; no revenue impact for pre-revenue biotech
Risk Factors
- Clinical trial failure or delays
- Dilution risk from future financing (cash runway to Q2 2028)
- No approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003154 |
| Document: f8k_050726.htm | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index-headers.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154.txt | 0001171843-26-003154 |
| 8-K Data (Synthetic) | 0001171843-26-003154 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers